Congenital Adrenal Hyperplasia Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates | Spruce Biosciences, Neurocrine Bioscience, BridgeBio Pharma, Crinetics Pharma., Millendo

The Key Congenital Adrenal Hyperplasia Companies in the market include - Neurocrine Biosciences, Spruce Biosciences, Neurocrine Bioscience, BridgeBio Pharma, Crinetics Pharmaceuticals Inc., Spruce Biosciences, Neurocrine Biosciences, Millendo Therapeutics, Inc, Adrenas Therapeutics Inc, Diurnal Limited, Novartis, and others.

DelveInsight's "Congenital Adrenal Hyperplasia Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Congenital Adrenal Hyperplasia, historical and forecasted epidemiology as well as the Congenital Adrenal Hyperplasia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Congenital Adrenal Hyperplasia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Congenital Adrenal Hyperplasia Market Forecast [https://www.delveinsight.com/sample-request/congenital-adrenal-hyperplasia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Congenital Adrenal Hyperplasia Market Report:

*
The Congenital Adrenal Hyperplasia market size was valued approximately USD 20 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034).

*
In August 2025, Crinetics Pharmaceuticals (Nasdaq: CRNX) reported that the FDA has awarded Orphan Drug Designation to atumelnant, a novel, first-in-class oral ACTH receptor antagonist taken once daily, for the treatment of classic congenital adrenal hyperplasia (CAH).

*
In May 2025, Neurocrine Biosciences, Inc. (Nasdaq: NBIX) has released new findings from its Phase 3 CAHtalyst Trademark Adult and Pediatric trials evaluating CRENESSITY Trademark (crinecerfont). The results revealed that a significant number of pediatric patients with classic congenital adrenal hyperplasia (CAH) reached glucocorticoid doses within the physiological range and achieved normal androstenedione levels. Furthermore, adult male patients showed improvements in certain reproductive hormone levels. Both groups-adults and children-experienced notable reductions in glucocorticoid dosing. These findings were shared at the 2025 Annual Meeting of the American Association of Clinical Endocrinology in Orlando.

*
In 2023, the United States dominated the Congenital Adrenal Hyperplasia market within the 7 major markets (7MM), representing about 60% of the overall market share.

*
In 2023, steroids were the leading therapy for Congenital Adrenal Hyperplasia in the United States. However, by 2034, BBP-631 is anticipated to become the dominant treatment, capturing the largest market share.

*
In 2023, steroid therapies for congenital adrenal hyperplasia generated around USD 7 million in revenue across the EU4 countries and the UK.

*
In the 7 major markets (7MM), the United States had the highest number of congenital adrenal hyperplasia cases in 2023, with approximately 32,000 individuals affected; this figure is projected to rise over the forecast period.

*
In 2023, congenital adrenal hyperplasia primarily impacted males in the US, with about 19,000 diagnosed cases in males compared to 13,000 in females.

*
In the 7 major markets (7MM), adults aged over 18 were the most affected by congenital adrenal hyperplasia, with around 36,000 cases reported in 2020. This figure is expected to rise to about 50,000 by 2034.

*
Among congenital adrenal hyperplasia cases caused by genetic mutations, 21-hydroxylase deficiency (CYP21A2 gene mutation) is more prevalent than 11-beta hydroxylase deficiency (CYP11B1 gene mutation) and other types.

*
Key Congenital Adrenal Hyperplasia Companies: Neurocrine Biosciences, Spruce Biosciences, Neurocrine Bioscience, BridgeBio Pharma, Crinetics Pharmaceuticals Inc., Spruce Biosciences, Neurocrine Biosciences, Millendo Therapeutics, Inc, Adrenas Therapeutics Inc, Diurnal Limited, Novartis, and others

*
Key Congenital Adrenal Hyperplasia Therapies: EFMODY (Hydrocortisone Modified-release Hard Capsules), Tildacerfont, NBI-74788, BBP-631, CRN04894, SPR001, Crinecerfont, ATR-101, AAV BBP-631, Chronocort, Osilodrostat, and others

*
The Congenital Adrenal Hyperplasia epidemiology based on gender analyzed that no gender related difference was observed in case of Congenital Adrenal Hyperplasia

*
The Congenital Adrenal Hyperplasia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Congenital Adrenal Hyperplasia pipeline products will significantly revolutionize the Congenital Adrenal Hyperplasia market dynamics.

Congenital Adrenal Hyperplasia Overview

Congenital Adrenal Hyperplasia is a group of inherited genetic disorders that affect the adrenal glands, which produce hormones like cortisol, aldosterone, and androgens. CAH is most commonly caused by a deficiency of the enzyme 21-hydroxylase, leading to insufficient cortisol and/or aldosterone and an overproduction of androgens (male hormones). This hormone imbalance can cause symptoms such as abnormal genital development in females, early puberty, rapid growth, and in severe cases, life-threatening salt-wasting crises. CAH is typically diagnosed at birth or in early childhood and is managed with hormone replacement therapy to maintain proper hormone levels.

Get a Free sample for the Congenital Adrenal Hyperplasia Market Report:

https://www.delveinsight.com/report-store/congenital-adrenal-hyperplasia-market [https://www.delveinsight.com/report-store/congenital-adrenal-hyperplasia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Congenital Adrenal Hyperplasia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Congenital Adrenal Hyperplasia Epidemiology Segmentation:

The Congenital Adrenal Hyperplasia market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Prevalence of Congenital Adrenal Hyperplasia

*
Prevalent Cases of Congenital Adrenal Hyperplasia by severity

*
Gender-specific Prevalence of Congenital Adrenal Hyperplasia

*
Diagnosed Cases of Episodic and Chronic Congenital Adrenal Hyperplasia

Download the report to understand which factors are driving Congenital Adrenal Hyperplasia epidemiology trends @ Congenital Adrenal Hyperplasia Epidemiology Forecast [https://www.delveinsight.com/sample-request/congenital-adrenal-hyperplasia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Congenital Adrenal Hyperplasia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Congenital Adrenal Hyperplasia market or expected to get launched during the study period. The analysis covers Congenital Adrenal Hyperplasia market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Congenital Adrenal Hyperplasia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Congenital Adrenal Hyperplasia Therapies and Key Companies

*
EFMODY (Hydrocortisone Modified-release Hard Capsules): Neurocrine Biosciences

*
Tebipenem Pivoxil Hydrobromide (SPR994): Spero Therapeutics

*
Cefepime/zidebactam (WCK-5222): Wockhardt

*
Cefepime/taniborbactam: Venatorx Pharmaceuticals

*
Tildacerfont: Spruce Biosciences

*
NBI-74788 Neurocrine Bioscience

*
BBP-631: BridgeBio Pharma

*
CRN04894: Crinetics Pharmaceuticals Inc.

*
SPR001: Spruce Biosciences

*
Crinecerfont: Neurocrine Biosciences

*
ATR-101: Millendo Therapeutics, Inc.

*
AAV BBP-631: Adrenas Therapeutics Inc

*
Chronocort: Diurnal Limited

*
Osilodrostat: Novartis

Discover more about therapies set to grab major Congenital Adrenal Hyperplasia market share @ Congenital Adrenal Hyperplasia Treatment Market [https://www.delveinsight.com/sample-request/congenital-adrenal-hyperplasia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Scope of the Congenital Adrenal Hyperplasia Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Congenital Adrenal Hyperplasia Companies: Neurocrine Biosciences, Spruce Biosciences, Neurocrine Bioscience, BridgeBio Pharma, Crinetics Pharmaceuticals Inc., Millendo Therapeutics, Inc, Adrenas Therapeutics Inc, Diurnal Limited, Novartis, and others

*
Key Congenital Adrenal Hyperplasia Therapies: EFMODY (Hydrocortisone Modified-release Hard Capsules), Tildacerfont, NBI-74788, BBP-631, CRN04894, SPR001, Crinecerfont, ATR-101, AAV BBP-631, Chronocort, Osilodrostat, and others

*
Congenital Adrenal Hyperplasia Therapeutic Assessment: Congenital Adrenal Hyperplasia current marketed and Congenital Adrenal Hyperplasia emerging therapies

*
Congenital Adrenal Hyperplasia Market Dynamics: Congenital Adrenal Hyperplasia market drivers and Congenital Adrenal Hyperplasia market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Congenital Adrenal Hyperplasia Unmet Needs, KOL's views, Analyst's views, Congenital Adrenal Hyperplasia Market Access and Reimbursement

To know more about Congenital Adrenal Hyperplasia companies working in the treatment market, visit @ Congenital Adrenal Hyperplasia Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/congenital-adrenal-hyperplasia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Congenital Adrenal Hyperplasia Market Report Introduction

2. Executive Summary for Congenital Adrenal Hyperplasia

3. SWOT analysis of Congenital Adrenal Hyperplasia

4. Congenital Adrenal Hyperplasia Patient Share (%) Overview at a Glance

5. Congenital Adrenal Hyperplasia Market Overview at a Glance

6. Congenital Adrenal Hyperplasia Disease Background and Overview

7. Congenital Adrenal Hyperplasia Epidemiology and Patient Population

8. Country-Specific Patient Population of Congenital Adrenal Hyperplasia

9. Congenital Adrenal Hyperplasia Current Treatment and Medical Practices

10. Congenital Adrenal Hyperplasia Unmet Needs

11. Congenital Adrenal Hyperplasia Emerging Therapies

12. Congenital Adrenal Hyperplasia Market Outlook

13. Country-Wise Congenital Adrenal Hyperplasia Market Analysis (2020-2034)

14. Congenital Adrenal Hyperplasia Market Access and Reimbursement of Therapies

15. Congenital Adrenal Hyperplasia Market Drivers

16. Congenital Adrenal Hyperplasia Market Barriers

17. Congenital Adrenal Hyperplasia Appendix

18. Congenital Adrenal Hyperplasia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=congenital-adrenal-hyperplasia-market-insights-highlight-expanding-outlook-till-2034-delveinsight-evaluates-spruce-biosciences-neurocrine-bioscience-bridgebio-pharma-crinetics-pharma-millendo]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.